Telemedicine in the Era of COVID-19: Mitigating Risk for People with Psoriasis and Psoriatic Arthritis

Released On
September 18, 2020

Expires On
September 18, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Dermatology, Primary Care, Rheumatology

Scroll to the Bottom of this Information to Begin this Course

Jointly provided by the Postgraduate Institute for Medicine and Catamount Medical Education

Supported by an independent educational grant from Pfizer

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to meet the educational needs of rheumatologists, dermatologists, primary care physicians, and other healthcare professionals who care for patients with psoriasis and psoriatic arthritis

Program Overview

A timely roundtable discussion with three distinguished faculty on COVID-19 and mitigating risks for people with psoriatic disease through the appropriate use of telemedicine.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the history of and current known facts related to COVID-19
  • Describe the risks of COVID-19 in people with psoriatic disease
  • Discuss opportunities for care via telemedicine for people with psoriatic disease
  • Employ best practices for implementation of telemedicine in psoriasis and psoriatic arthritis management

Faculty

Abby S. Van Voorhees, MD, (Chairperson)

Professor, Chair and Program Director
Eastern Virginia Medical School, Department of Dermatology
Norfolk, VA

Robin K. Dore, MD

Clinical Professor of Medicine, UCLA
Los Angeles, CA
Private Practice Rheumatology
Tustin, CA

Ian Frank, MD

Professor of Medicine
Associate Chief
Infectious Diseases Division
Perelman School of Medicine
University of Pennsylvania

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Catamount Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Abby S. Van Voorhees, MD, (Chairperson)

  • Consulting Fees: Celgene
  • Contracted Research: AbbVie, Celgene, Lilly

Robin K. Dore, MD

  • Consulting Fees: Lilly, Novartis
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents: AbbVie, Lilly, Novartis
  • Contracted Research: Lilly, Novartis

Ian Frank, MD

  • Consulting Fees: Gilead, GlaxoSmithKline, ViiV Healthcare
  • Contracted Research: Janssen

Planners and Managers

The PIM planners and managers have nothing to disclose. The Catamount Medical Education planners and managers have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. Participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgement for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test (at least two out of three answers correct) and the activity evaluation, your certificate will be emailed.

Hardware and Software Requirements

CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.